etn. — the European Technology Network — is Europe's daily live technology show. It broadcasts three hours a day from a studio in King's Cross, London, covering European startups, frontier AI labs and technology policy, and streams free on X and YouTube.

etn. is hosted by its co-founders, Luke Knight and Ronan Chambers, who started the show in October 2025.

etn. is live every weekday, Monday to Friday, from 12:00 to 15:00 UK time, followed by long-form guest interviews.

Where can I watch etn.?

etn. streams live on X and YouTube, and full episodes are published as a podcast on Spotify. Watching is free and requires no subscription.

Who has appeared on etn.?

Guests have included former UK Prime Minister Rishi Sunak, the UK's first AI minister Kanishka Narayan, Sequoia partner George Robson, and founders from Synthesia, Legora and Granola.

etn. raised a $1.6 million seed round announced in July 2026, backed by Powerhouse Capital, Axel Springer SE, a co-founder of LADbible, and angel investors from OpenAI and Google DeepMind.

Amine Raji

Co-Founder & CEO of Spore.Bio

1 episode · 1 moment · last on 14 Jan 2026

14 Jan 2026Eleven Labs $300M ARR, Claude Cowork, Google’s Apple, HartmanAI $200M

2:30:5423 min

Spore.Bio Founder Live: 10-Minute Bacteria Detection & Google.org Backing

A Paris-based biotech founder joins live (calling from San Francisco at 5am during JPM Healthcare) to celebrate Spore.Bio being the only startup among ten projects selected by Google.org's AI-for-science initiative, bringing philanthropic funding, DeepMind collaboration on antimicrobial resistance, free compute, a new AI-native lab in Paris, and a planned New York office. He explains their technology detects, quantifies, and identifies bacteria in 10 minutes instead of the 5-14 days required by petri dishes, shares the founding story of a massive recall at his previous company and meeting his microbiology researcher co-founder, and describes the roughly $10M-per-recall pain, 480,000 annual contamination deaths, strong inbound demand from Fortune 500 manufacturers, and following pharma manufacturing to the US amid Trump-era reshoring.